ECSP088335A - Compuestos de pirimidina amida como inhibidores de pgds - Google Patents

Compuestos de pirimidina amida como inhibidores de pgds

Info

Publication number
ECSP088335A
ECSP088335A EC2008008335A ECSP088335A ECSP088335A EC SP088335 A ECSP088335 A EC SP088335A EC 2008008335 A EC2008008335 A EC 2008008335A EC SP088335 A ECSP088335 A EC SP088335A EC SP088335 A ECSP088335 A EC SP088335A
Authority
EC
Ecuador
Prior art keywords
amida
pyrimidine compounds
compound
pgds inhibitors
pgds
Prior art date
Application number
EC2008008335A
Other languages
English (en)
Inventor
Suzanne C Aldous
John Ziqi Jiang
Jinqi Lu
Liang Ma
Lan Mu
Harry Randall Munson
Jeffrey Stephen Sabol
Sukanthini Thurairatnam
Christopher Loren Vandeusen
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of ECSP088335A publication Critical patent/ECSP088335A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Esta invención se refiere a un compuesto de fórmula (I):en la que R1, R2, R3 y L1 son como se han definido anteriormente, una composición farmacéutica que comprende el compuesto, y el uso del compuesto para tratar trastornos alérgicos y/o inflamatorios, particularmente trastornos tales como rinitis alérgica, asma y/o enfermedad pulmonar obstructiva crónica (COPD).
EC2008008335A 2005-10-04 2008-04-02 Compuestos de pirimidina amida como inhibidores de pgds ECSP088335A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72357005P 2005-10-04 2005-10-04

Publications (1)

Publication Number Publication Date
ECSP088335A true ECSP088335A (es) 2008-05-30

Family

ID=37635758

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008335A ECSP088335A (es) 2005-10-04 2008-04-02 Compuestos de pirimidina amida como inhibidores de pgds

Country Status (27)

Country Link
US (1) US8202863B2 (es)
EP (1) EP1937652B1 (es)
JP (1) JP5452925B2 (es)
KR (1) KR101457966B1 (es)
CN (2) CN101282943A (es)
AR (1) AR056871A1 (es)
AU (1) AU2006299428B2 (es)
BR (1) BRPI0616815A2 (es)
CA (1) CA2624749C (es)
CR (1) CR9832A (es)
DO (1) DOP2006000210A (es)
EC (1) ECSP088335A (es)
ES (1) ES2514471T3 (es)
IL (1) IL190411A (es)
MA (1) MA29925B1 (es)
MY (1) MY151172A (es)
NO (1) NO20082000L (es)
NZ (1) NZ567208A (es)
PE (2) PE20110118A1 (es)
RU (1) RU2420519C2 (es)
SG (1) SG166121A1 (es)
TN (1) TNSN08104A1 (es)
TW (1) TWI415839B (es)
UA (1) UA93213C2 (es)
UY (1) UY29840A1 (es)
WO (1) WO2007041634A1 (es)
ZA (1) ZA200802222B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1931642A4 (en) * 2005-09-15 2011-06-01 Orchid Res Lab Ltd NEW PYRIMIDINE CARBOXAMIDES
PE20110118A1 (es) 2005-10-04 2011-03-08 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds
KR20080109918A (ko) 2006-04-11 2008-12-17 버텍스 파마슈티칼스 인코포레이티드 전압 개폐 나트륨 채널의 억제제로서 유용한 조성물
CA2672373C (en) 2006-12-19 2011-08-30 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
JP2010519328A (ja) 2007-02-26 2010-06-03 ファイザー・プロダクツ・インク Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体およびプロスタグランジンｄ２が媒介する疾患の治療のためのそれらの使用
CA2696609C (en) 2007-08-27 2017-09-05 Helicon Therapeutics, Inc. Therapeutic isoxazole compounds
EP2227453B1 (en) * 2007-10-11 2016-03-09 Vertex Pharmaceuticals Incorporated Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
RU2010118467A (ru) 2007-10-11 2011-11-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ариламиды, пригодные в качестве ингибиторов потенциалзависимых натриевых каналов
RU2010118481A (ru) 2007-10-11 2011-11-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Амиды, применимые в качестве ингибиторов потенциалзависимых натриевых каналов
US8153651B2 (en) * 2007-11-13 2012-04-10 Evotec Ag Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2009099086A1 (ja) * 2008-02-06 2009-08-13 Banyu Pharmaceutical Co., Ltd. ３位置換スルホニルピペリジン誘導体
AU2009246446B2 (en) * 2008-05-13 2014-06-26 Cayman Chemical Company, Incorporated Methods for assaying compounds or agents for ability to displace potent ligands of hematopoietic prostaglandin D synthase
EP2307378A1 (en) 2008-06-18 2011-04-13 Pfizer Limited Nicotinamide derivatives
CA2724998A1 (en) 2008-06-18 2009-12-23 Pfizer Limited Nicotinamide derivatives
AP3272A (en) 2008-09-22 2015-05-31 Cayman Chem Co Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prosaglandin D2 mediated diseases
KR101367057B1 (ko) 2009-03-17 2014-02-25 (주)아모레퍼시픽 피부 자극 완화용 조성물
WO2010056044A2 (ko) * 2008-11-11 2010-05-20 (주)아모레퍼시픽 바닐로이드 수용체 길항제로 작용하는 신규 화합물, 이의 이성질체 또는 이의 약제학적으로 허용 가능한 염 및 이를 포함하는 약학 조성물
KR101252335B1 (ko) 2009-07-16 2013-04-08 (주)아모레퍼시픽 피부 노화 방지용 조성물
CN102341385B (zh) 2009-03-09 2014-01-15 大鹏药品工业株式会社 能够抑制前列腺素d合酶的哌嗪化合物
PH12012500676A1 (en) * 2009-10-08 2015-06-03 Sanofi Sa Phenyloxadiazole derivatives as pgds inhibitors
PH12012501385A1 (en) 2010-01-22 2014-10-22 Taiho Pharmaceutical Co Ltd Piperazine compound having a pgds inhibitory effect
US9320723B2 (en) * 2010-05-03 2016-04-26 University Of Rochester Methods of treating thyroid eye disease
EP2576536B1 (en) 2010-06-01 2016-09-14 The University of Queensland Haematopoietic-prostaglandin d2 synthase inhibitors
JP5693591B2 (ja) 2010-09-07 2015-04-01 大鵬薬品工業株式会社 プロスタグランジンｄ合成酵素を阻害するピペリジン化合物
KR101271223B1 (ko) 2011-01-27 2013-06-07 한국과학기술연구원 아미노피리미딘 유도체 및 이를 포함하는 세포외 신호조절 키나제의 제해제
EP2800568A4 (en) 2012-01-06 2015-06-10 Univ South Florida COMPOSITIONS, USE METHOD AND TREATMENT METHOD THEREFOR
PL2888241T3 (pl) * 2012-08-24 2017-12-29 Sunshine Lake Pharma Co., Ltd. 2,4,5,6-Podstawione pochodne 3,6-dihydropirymidyny jako inhibitory polimerazy wirusa zapalenia wątroby typu B (HBV) do leczenia np. przewlekłego zapalenia wątroby
CN108430992A (zh) 2015-12-17 2018-08-21 阿斯特克斯医疗公司 作为h-pgds抑制剂的喹啉-3-甲酰胺
WO2017160832A1 (en) * 2016-03-14 2017-09-21 Emory University Amide-sulfamide derivatives, compositions, and uses related to cxcr4 inhibition
JOP20190072A1 (ar) 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
WO2018229629A1 (en) 2017-06-13 2018-12-20 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as h-pgds inhibitors
WO2019084529A1 (en) * 2017-10-29 2019-05-02 China Medical University ADAM9 INHIBITORS AND USES THEREOF
EP3724197A1 (en) 2017-12-13 2020-10-21 GlaxoSmithKline Intellectual Property Development Ltd Fused pyridines which act as inhibitors of h-pgds
IL277455B2 (en) * 2018-03-23 2024-05-01 Step Pharma S A S Aminopyrimidine derivatives as ctps1 inhibitors
US20220009918A1 (en) 2018-11-08 2022-01-13 Glaxosmithkline Intellectual Property Development Limited Chemical Compounds
CN116997548A (zh) 2020-05-13 2023-11-03 Chdi基金会股份有限公司 用于治疗亨廷顿病的htt调节剂
CN115667259B (zh) 2020-06-19 2025-06-17 佐藤制药株式会社 抑制h-pgds的稠环化合物
EP4232425A4 (en) * 2020-10-23 2024-07-24 Nimbus Clotho, Inc. Ctps1 inhibitors and uses thereof
CN113004208A (zh) * 2021-03-08 2021-06-22 沈阳药科大学 一种抑制黄嘌呤氧化酶活性的化合物及制备方法和应用
US12281116B2 (en) 2021-11-17 2025-04-22 Chdi Foundation, Inc. HTT modulators for treating Huntington's disease
CN118401522A (zh) 2021-12-17 2024-07-26 佐藤制药株式会社 抑制h-pgds的氮杂吲哚衍生物
AR128619A1 (es) * 2022-02-28 2024-05-29 Japan Tobacco Inc Compuesto de indazol y su uso farmacéutico

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2934543A1 (de) * 1979-08-27 1981-04-02 Basf Ag, 6700 Ludwigshafen Substituierte n-benzoylanthranilsaeurederivate und deren anydroverbindungen, verfahren zu ihrer herstellung und ihre verwendung als herbizide
JPH03112985A (ja) * 1989-09-28 1991-05-14 Morishita Pharmaceut Co Ltd Ｎ―（１ｈ―テトラゾール―５―イル）―２―フェニル―５―ピリミジンカルボキシアミド類及びその合成用中間体
GB9405347D0 (en) * 1994-03-18 1994-05-04 Agrevo Uk Ltd Fungicides
JP2000226372A (ja) * 1999-02-01 2000-08-15 Nippon Soda Co Ltd アミド化合物、その製造方法及び農園芸用殺虫剤
WO2001021577A2 (en) * 1999-09-20 2001-03-29 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist
JP2002003370A (ja) * 1999-09-20 2002-01-09 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
MY138097A (en) * 2000-03-22 2009-04-30 Du Pont Insecticidal anthranilamides
JP2003112985A (ja) 2001-10-01 2003-04-18 Nre Happiness Kk 食品残渣肥、飼料原料化システムおよびそれに使用する破砕貯留処理ユニット並びに乾燥冷却処理ユニット
JPWO2004011430A1 (ja) * 2002-07-25 2005-11-24 アステラス製薬株式会社 ナトリウムチャネル阻害剤
DE60329513D1 (de) * 2002-07-30 2009-11-12 Banyu Pharma Co Ltd Antagonist des melanin-concentrating-hormone-rezeptors, enthaltend ein benzimidazolderivat als wirkstoff
ES2337254T3 (es) * 2003-02-14 2010-04-22 Glaxo Group Limited Derivados de carboxamida.
ATE316077T1 (de) * 2003-04-25 2006-02-15 Actimis Pharmaceuticals Inc Pyrimidin-essigsäure derivate geeignet zur behandlung von crth2-bedingten krankheiten
JP2007525482A (ja) * 2003-10-07 2007-09-06 レノビス， インコーポレイテッド イオンチャネルリガンドとしてのアミド化合物およびその使用
US20050165028A1 (en) * 2004-01-23 2005-07-28 Norman Mark H. Vanilloid receptor ligands and their use in treatments
PE20110118A1 (es) 2005-10-04 2011-03-08 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds

Also Published As

Publication number Publication date
JP5452925B2 (ja) 2014-03-26
JP2009510170A (ja) 2009-03-12
ES2514471T3 (es) 2014-10-28
EP1937652B1 (en) 2014-07-30
AU2006299428A1 (en) 2007-04-12
MA29925B1 (fr) 2008-11-03
ZA200802222B (en) 2009-09-30
PE20110118A1 (es) 2011-03-08
CA2624749A1 (en) 2007-04-12
CA2624749C (en) 2011-08-16
IL190411A0 (en) 2008-11-03
CR9832A (es) 2008-06-18
RU2008117170A (ru) 2009-11-10
NO20082000L (no) 2008-06-09
TWI415839B (zh) 2013-11-21
TNSN08104A1 (en) 2009-07-14
DOP2006000210A (es) 2007-06-15
TW200812977A (en) 2008-03-16
PE20070589A1 (es) 2007-06-22
SG166121A1 (en) 2010-11-29
KR20080050611A (ko) 2008-06-09
IL190411A (en) 2013-09-30
AU2006299428B2 (en) 2012-04-26
CN101538246B (zh) 2014-07-16
BRPI0616815A2 (pt) 2011-07-05
MY151172A (en) 2014-04-30
RU2420519C2 (ru) 2011-06-10
EP1937652A1 (en) 2008-07-02
US20080227782A1 (en) 2008-09-18
UY29840A1 (es) 2007-05-31
CN101282943A (zh) 2008-10-08
UA93213C2 (en) 2011-01-25
CN101538246A (zh) 2009-09-23
KR101457966B1 (ko) 2014-11-04
WO2007041634A1 (en) 2007-04-12
AR056871A1 (es) 2007-10-31
US8202863B2 (en) 2012-06-19
NZ567208A (en) 2011-03-31

Similar Documents

Publication Publication Date Title
ECSP088335A (es) Compuestos de pirimidina amida como inhibidores de pgds
SV2009002861A (es) Compuestos de pirimidina amida como inhibidores de pgds
MX2009009443A (es) Compuestos de pirimidina hidrazida como inhibidores de pgds.
ECSP14013173A (es) 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil) carbamimidoil)pirazina-2-carboxamida
SV2008003045A (es) Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes
BR0107934A (pt) Carboxamidas de pirimidina úteis como inibidores de isozimas pde4
NI201100081A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa - iv para el tratamiento o prevención de diabetes.
GT200600193A (es) Imidazoquinolines como inhibidores de lipidos kinase
GT200900289A (es) Compuestos organicos.-
UY32938A (es) Derivados de feniloxadiazol como agentes inhibidores de las pgds
CL2011002787A1 (es) Compuestos derivados de 1-cianoetilheterociclilcarboxamida sustituidos, inhibidores de dipeptidilpeptidasa i (dppi) o catepsina c; composicion farmaceutica; combinacion faramceutica; y su uso en el tratamiento del asma, la enfermedad obstructiva cronica o la rinitis alergica.
NO20075113L (no) Proteinkinaseinhibitorer
UY29506A1 (es) Nuevas formas cristalinas de bromuro de tiotropio
CL2011002463A1 (es) Compuestos heterociclicos, agonistas del receptor de glucocorticoide; composicion farmaceutica que comprende a dicho compuesto; composicion farmaceutica; kit farmaceutico; uso del compuesto para tratar el asma, enfermedad pulmonar obstructiva cronica o rinitis alergica.
CL2011002461A1 (es) Compuestos derivados de tipo amida de compuestos [3,2-c] pirazol con actividad glucocorticoide utiles en condiciones inflamatorias y alergicas como asma, epoc o rinitis alergica.
CL2008003495A1 (es) Compuestos derivados de pirazol; composicion farmaceutica, metodo de preparacion y; su uso para tratar una enfermedad mediada por 5-lo tal como asma, broncocontriccion, enfisema, enfermedades obstructivas o inflamatorias de las vias respiratorias, bronquitis, lesion pulmonar aguda, bronquiectasia, rinitis alergica, entre otras.
EA201070927A1 (ru) Двойные фармакофоры-pde4-мускариновые антагонисты
NO20081483L (no) Kombinasjon av forbindelser som kan brukes ved behandling av respiratoriske sykdommer, spesielt kronisk obstruktiv pulmonaer sykdom (COPD) og astma
DOP2010000239A (es) Farmacoforos duales-antagonistas muscarinicos de pde4
UY30988A1 (es) Compuestos de pirimidina hidrazida como inhibidores de pgds
CL2012000885A1 (es) Compuestos derivados de feniloxadiazol, inhibidores de las prostaglandinas sintasa (pgds); procedimiento de preparacion de dichos compuestos; compuestos intermediarios; composicion farmaceutica que comprende dichos compuestos, util para tratar un trastorno inflamatorio o alergico.
GT200500056A (es) Compuestos utiles para el tratamiento de enfermedades
BRPI0509137A (pt) compostos para o tratamento de doenças
CL2011001061A1 (es) Compuestos derivados de pirazolona, inhibidores de fosfodiesterasa tipo 4 (pdea); composicion farmaceutica; y uso para el tratamiento o la profilaxis de una enfermedad aguda o cronica de las vias respiratorias, tal como bronquitis, asma, enfisema y para el tratamiento o profilaxis de rinitis alergica.
DOP2005000174A (es) Fenilaminotiazoles sustituidos y su uso